Researchers named to National Academy of Inventors

December 11, 2013

(SALT LAKE CITY)--Three University of Utah Health Sciences faculty members whose research has resulted in major disease-related discoveries, numerous patents, biomedical inventions, and startup companies have been named fellows of the National Academy of Inventors (NAI).

Carl W. Wittwer, M.D., Ph.D., professor of pathology and research scientist at ARUP Laboratories, Lisa Cannon-Albright, Ph.D., professor of internal medicine and chief of the Division of Genetic Epidemiology at the U School of Medicine, and Glenn D. Prestwich, Ph.D., presidential professor of medicinal chemistry and special presidential assistant for faculty entrepreneurism, will be formally inducted into the NAI during a March ceremony.

They are among 143 innovators elected as fellows to the NAI this year. Election to NAI Fellow status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

Thomas N. Parks, Ph.D., University of Utah vice president for research, nominated the three U of U faculty members as fellows for the NAI. "The University of Utah has a deep bench of accomplished faculty researchers whose work has had practical applications that benefit society," says Parks, a charter NAI fellow. "Drs. Wittwer, Prestwich and Cannon-Albright have contributed significantly to their fields. Their innovations and discoveries exemplify the creativity and entrepreneurship that result in products and ideas that help people worldwide."

Wittwer, who came to the School of Medicine in 1988, has been a pioneer in developing polymerase chain reaction (PCR) techniques for analyzing DNA and holds 34 U.S. patents in this area. He is the primary inventor of the LightCycler real-time PCR system, with over 10,000 units in service worldwide. He co-founded BioFire Diagnostics (previously known as Idaho Technology), a company with 500 employees that provides the U.S. government with a rapid PCR platform for military defense against biologic weapons.

Cannon-Albright has used biomedical informatics to develop the analytical methods for using the unique family-based genetic resource known as the Utah Population Database to look for disease-causing gene mutations in large, multigenerational families. Working with other University of Utah researchers, she has contributed to seminal discoveries of mutations related to hereditary breast cancer, melanoma and colon cancer. Recently, she identified a prostate cancer susceptibility gene. Several of her discoveries have led to patented technologies, some of which have formed the basis for new diagnostic tests. She came to the University in 1988.

Prestwich, who joined the University's College of Pharmacy in 1996, has been a prolific researcher, inventor and entrepreneur for over 30 years. His work first led to chemical tools used for research in lipid signaling and drug discovery in cancer. Additional inventions consist of hyaluronic acid hydrogels that facilitate rapid wound healing and also are used for cell therapy and regenerative medicine. The latest patents support the development of drugs to treat chronic inflammation of the bladder and periodontal tissues. These inventions, and others, comprise more than 27 patents and have led Prestwich to found eight companies, including Echelon Biosciences, Glycosan Biosystems (now BioTime), and GlycoMira Therapeutics.

"One of the better kept secrets in academic medicine is the caliber of innovative researchers and clinicians we have at the University of Utah Health Sciences," says Vivian Lee, MD, PhD, M.B.A., senior vice president for health sciences, dean of the School of Medicine and CEO of University of Utah Health Care. "As academic medical centers, advancing the science and delivery of health care is key to our ability to innovate health care reform. We are so proud of Dr.'s Wittwer, Prestwich and Cannon-Albright for their work on this front, and for this recognition."

Prestwich, Cannon-Albright and Wittwer join four other U of U faculty and administrators who are charter NAI fellows: President David W. Pershing, Ph.D., a chemical engineer, Stephen C. Jacobsen, Ph.D., distinguished professor emeritus of mechanical engineering, Sung Wan Kim, Ph.D., distinguished professor of pharmaceutics and pharmaceutical chemistry and bioengineering, and Parks, a neurobiologist, former chair of the Department of Neurobiology and Anatomy and co-founder of NPS Pharmaceuticals.

The 143 innovators elected to NAI Fellow status represent 94 universities and governmental and non-profit research institutes. Included in the 2013 class are 26 presidents and senior leadership of research universities and non-profit research institutes, 69 members of the National Academies (Institute of Medicine, National Academy of Sciences, National Academy of Engineering), five inductees of the National Inventors Hall of Fame, six recipients of the U.S. National Medal of Technology and Innovation, two recipients of the U.S. National Medal of Science and nine Nobel Laureates.

Deputy U.S. Commissioner for Patents Andy Faile, from the United States Patent and Trademark Office, will induct the new fellows during the 3rd Annual Conference of the National Academy of Inventors, on Mar. 7, 2014, in Alexandria, Va., at the headquarters of the United States Patent and Trademark Office. Fellows will be presented with a special trophy and a rosette pin.

The NAI Fellows Selection Committee comprises 13 Members, including NAI Charter Fellows, recipients of U.S. National Medals, National Inventors Hall of Fame inductees, members of the National Academies and senior officials from the United States Patent and Trademark Office, the American Association for the Advancement of Science and the Association of University Technology Managers.
-end-


University of Utah Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.